KKR Entity Amends Stake in BridgeBio Pharma

TL;DR

KKR entity just updated its stake in BridgeBio Pharma. Watch this one.

AI Summary

On September 17, 2024, KKR Genetic Disorder L.P. filed an amendment (Amendment No. 4) to its Schedule 13D regarding BridgeBio Pharma, Inc. The filing indicates a change in beneficial ownership, with KKR Genetic Disorder L.P. now holding a significant stake in BridgeBio Pharma, Inc. The specific percentage and number of shares are detailed within the filing.

Why It Matters

This filing signals a potential shift in control or influence for BridgeBio Pharma, Inc., which could impact its strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership by significant investment firms can lead to increased volatility and strategic shifts for the target company.

Key Players & Entities

• KKR Genetic Disorder L.P. (company) — Filing entity
• BridgeBio Pharma, Inc. (company) — Subject company
• George R. Roberts (person) — Group member
• Henry R. Kravis (person) — Group member
• KKR & Co. Inc. (company) — Group member

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie
• $25.75 — mon Stock in a block sale at a price of $25.75 per share pursuant to Rule 144 under th

Filing Documents

• ef20035948_sc13da.htm (SC 13D/A) — 343KB
• ef20035948_ex99-1.htm (EX-99.1) — 19KB
• 0001140361-24-041327.txt ( ) — 364KB

of the Schedule 13D is hereby amended and restated as follows

Item 2 of the Schedule 13D is hereby amended and restated as follows: (a), (f) This Schedule 13D is being jointly filed pursuant to Rule 13d-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), by: (i) KKR Genetic Disorder L.P., a Delaware limited partnership ("KKR Genetic Disorder"); (ii) KKR Genetic Disorder GP LLC, a Delaware limited liability company ("KKR Genetic Disorder GP"); (iii) KKR Group Partnership L.P., a Cayman Islands exempted limited partnership ("KKR Group Partnership"); (iv) KKR Group Holdings Corp., a Delaware corporation ("KKR Group Holdings"); (v) KKR Group Co. Inc., a Delaware corporation ("KKR Group Co."); (vi) KKR & Co. Inc., a Delaware corporation ("KKR & Co."); (vii) KKR Management LLP, a Delaware limited liability partnership ("KKR Management"); (viii) Henry R. Kravis, a United States citizen; and (ix) George R. Roberts, a United States citizen (the persons and entities listed in items (i) through (ix) are collectively referred to herein as the "Reporting Persons"). KKR Genetic Disorder GP is the general partner of KKR Genetic Disorder. KKR Group Partnership is the sole member of KKR Genetic Disorder GP. KKR Group Holdings is the general partner of KKR Group Partnership. KKR Group Co. is the sole shareholder of KKR Group Holdings. KKR & Co. is the sole shareholder of KKR Group Co. KKR Management is the Series I preferred stockholder of KKR & Co. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management. Each of Joseph Bae, Scott Nuttall, Robert Lewin, Ryan Stork, Dane Holmes, and Kathryn King Sudol is an executive officer of KKR Group Holdings and KKR Group Co. The directors of KKR Group Holdings and KKR Group Co. are Messrs. Bae, Nuttall, Lewin, and Stork and Ms. Sudol. The executive officers of KKR & Co. are Messrs. Kravis, Roberts, Bae, Nuttall, Lewin, Stork and Holmes and Ms. Sudol. The directors of KKR & Co. are listed on the amended and restat

of the Schedule 13D is hereby amended and supplemented as follows

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 5(c) below is incorporated by reference herein. Item 5. Interest in Securities of the Issuer. Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows: The information set forth in Items 2 and 3 and the amended and restated Annex A of this Schedule 13D and the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. (a) – (b) KKR Genetic Disorder holds 25,260,971 shares of Common Stock representing approximately 13.4% of the outstanding shares of Common Stock, based on 188,032,738 shares of Common Stock outstanding as of July 25, 2024, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 1, 2024. Each of KKR Genetic Disorder GP (as the general partner of KKR Genetic Disorder), KKR Group Partnership (as the sole member of KKR Genetic Disorder GP), KKR Group Holdings (as the general partner of KKR Group Partnership), KKR Group Co. (as the sole shareholder of KKR Group Holdings), KKR & Co. (as the sole shareholder of KKR Group Co.), KKR Management (as the Series I preferred stockholder of KKR & Co.) and Messrs. Kravis and Roberts (as the founding partners of KKR Management) may be deemed to be the beneficial owner of the securities held directly by KKR Genetic Disorder, in each case, as described more fully in this Schedule 13D. The filing of this Schedule 13D shall not be construed as an admission that any of the above-listed entities or individuals is the beneficial owner of any securities covered by this Schedule 13D. To the best knowledge of the Reporting Persons, none of the individuals named in Item 2 beneficially owns any shares of Common Stock except as described herein. (c) On September 13, 2024, KKR Genetic Disorder sold 5,800,000 shares of Common Stock in a block sale at a price of $25.75 per share pursuant to Rule 144 under the Securities Act of

of the Schedule 13D is hereby amended and supplemented as follows

Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit Number Description Exhibit I Joint Filing Agreement, dated as of September 17, 2024, by and among the Reporting Persons. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: September 17, 2024 KKR GENETIC DISORDER L.P. By: KKR Genetic Disorder GP LLC, its general partner By: /s/ Christopher Lee Name: Christopher Lee Title: Assistant Secretary KKR GENETIC DISORDER GP LLC By: /s/ Christopher Lee Name: Christopher Lee Title: Assistant Secretary KKR GROUP PARTNERSHIP L.P. By: KKR Group Holdings Corp., its general partner By: /s/ Christopher Lee Name: Christopher Lee Title: Secretary KKR GROUP HOLDINGS CORP. By: /s/ Christopher Lee Name: Christopher Lee Title: Secretary KKR GROUP CO. INC. By: /s/ Christopher Lee Name: Christopher Lee Title: Secretary KKR & CO. INC. By: /s/ Christopher Lee Name: Christopher Lee Title: Secretary KKR MANAGEMENT LLP By: /s/ Christopher Lee Name: Christopher Lee Title: Assistant Secretary HENRY R. KRAVIS By: /s/ Christopher Lee Name: Christopher Lee Title: Attorney-in-fact GEORGE R. ROBERTS By: /s/ Christopher Lee Name: Christopher Lee Title: Attorney-in-fact Annex A Annex A is hereby amended and restated as follows: Directors of KKR & Co. Inc. The following sets forth the name and principal occupation of each of the directors of KKR & Co. Inc., whose address (unless otherwise specified in the Schedule 13D) is c/o KKR & Co. Inc., 30 Hudson Yards, New York, New York, 10001. Each of such persons is a citizen of the United States other than Arturo Gutirrez Hernndez, who is a citizen of Mexico, Xavier B. Niel, who is a citizen of France, Evan T. Spiegel, who is a citizen of the United States and France, and Matthew R. Cohler, who is a citizen of the United States and M

View Full Filing

View this SC 13D/A filing on SEC EDGAR